USD 1.36
(0.74%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 | 13.77 Million USD | 33.07% |
2023 | 10.35 Million USD | -16.17% |
2022 | 12.35 Million USD | -39.45% |
2021 | 20.4 Million USD | 724.05% |
2020 | 2.47 Million USD | 6.34% |
2019 | 2.32 Million USD | -6.73% |
2018 | 2.49 Million USD | 274.07% |
2017 | 667.22 Thousand USD | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q2 | 8.82 Million USD | 1.45% |
2024 Q3 | 17.03 Million USD | 93.03% |
2024 FY | 13.77 Million USD | 33.07% |
2024 Q4 | 13.77 Million USD | -19.13% |
2024 Q1 | 8.7 Million USD | -15.97% |
2023 FY | 10.35 Million USD | -16.17% |
2023 Q1 | 10.15 Million USD | -17.75% |
2023 Q4 | 10.35 Million USD | -2.94% |
2023 Q3 | 10.66 Million USD | -40.89% |
2023 Q2 | 18.04 Million USD | 77.64% |
2022 Q4 | 12.35 Million USD | -13.98% |
2022 FY | 12.35 Million USD | -39.45% |
2022 Q3 | 14.35 Million USD | -5.76% |
2022 Q1 | 19.1 Million USD | -6.34% |
2022 Q2 | 15.23 Million USD | -20.26% |
2021 Q4 | 20.4 Million USD | 16.89% |
2021 Q2 | 19.96 Million USD | 587.04% |
2021 FY | 20.4 Million USD | 724.05% |
2021 Q1 | 2.9 Million USD | 17.39% |
2021 Q3 | 17.45 Million USD | -12.59% |
2020 Q1 | 3.06 Million USD | 31.57% |
2020 Q3 | 1.93 Million USD | 0.0% |
2020 FY | 2.47 Million USD | 6.34% |
2020 Q4 | 2.47 Million USD | 27.89% |
2019 Q3 | 2.07 Million USD | 0.0% |
2019 FY | 2.32 Million USD | -6.73% |
2019 Q4 | 2.32 Million USD | 12.36% |
2018 Q4 | 2.49 Million USD | 0.0% |
2018 FY | 2.49 Million USD | 274.07% |
2017 FY | 667.22 Thousand USD | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
Aclaris Therapeutics, Inc. | 197.4 Million USD | 93.02% |
Applied DNA Sciences, Inc. | 13.65 Million USD | -0.932% |
Aspira Women's Health Inc. | 6.26 Million USD | -120.039% |
Biodesix, Inc. | 99.09 Million USD | 86.095% |
BioNexus Gene Lab Corp. | 11.39 Million USD | -20.869% |
bioAffinity Technologies, Inc. | 8.22 Million USD | -67.594% |
bioAffinity Technologies, Inc. | 8.22 Million USD | -67.594% |
Bionano Genomics, Inc. | 214.4 Million USD | 93.573% |
CareDx, Inc | 484.61 Million USD | 97.157% |
Check-Cap Ltd. | 25.01 Million USD | 44.922% |
Castle Biosciences, Inc. | 477.81 Million USD | 97.116% |
DarioHealth Corp. | 96.38 Million USD | 85.705% |
Exact Sciences Corporation | 6.47 Billion USD | 99.787% |
Fulgent Genetics, Inc. | 1.27 Billion USD | 98.918% |
Guardant Health, Inc. | 1.78 Billion USD | 99.229% |
ICON Public Limited Company | 16.98 Billion USD | 99.919% |
IDEXX Laboratories, Inc. | 3.25 Billion USD | 99.577% |
Illumina, Inc. | 10.11 Billion USD | 99.864% |
iSpecimen Inc. | 15.81 Million USD | 12.898% |
Standard BioTools Inc. | 323.06 Million USD | 95.735% |
MDxHealth SA | 129.13 Million USD | 89.33% |
23andMe Holding Co. | 395.16 Million USD | 96.513% |
Medpace Holdings, Inc. | 1.65 Billion USD | 99.168% |
Myriad Genetics, Inc. | 1.19 Billion USD | 98.851% |
Mainz Biomed B.V. | 15.4 Million USD | 10.579% |
ENDRA Life Sciences Inc. | 6.75 Million USD | -104.006% |
NeoGenomics, Inc. | 1.68 Billion USD | 99.18% |
Neogen Corporation | 4.58 Billion USD | 99.699% |
Inotiv, Inc. | 856.53 Million USD | 98.391% |
Natera, Inc. | 1.45 Billion USD | 99.054% |
OPKO Health, Inc. | 2.01 Billion USD | 99.315% |
Psychemedics Corporation | 13.27 Million USD | -3.835% |
Prenetics Global Limited | 254.17 Million USD | 94.579% |
Prenetics Global Limited | 254.17 Million USD | 94.579% |
Precipio, Inc. | 18.1 Million USD | 23.878% |
Personalis, Inc. | 225.09 Million USD | 93.879% |
RadNet, Inc. | 2.88 Billion USD | 99.523% |
Sera Prognostics, Inc. | 95.44 Million USD | 85.563% |
Sotera Health Company | 3.13 Billion USD | 99.56% |
Neuronetics, Inc. | 115.83 Million USD | 88.104% |
Star Equity Holdings, Inc. | 86.97 Million USD | 84.157% |
Star Equity Holdings, Inc. | 86.97 Million USD | 84.157% |
Trinity Biotech plc | 59.43 Million USD | 76.817% |
Twist Bioscience Corporation | 776.4 Million USD | 98.225% |
Exagen Inc. | 56.94 Million USD | 75.803% |